Product analysis
No-Flush Niacin 500 mg offers a clearly labeled inositol hexanicotinate supplement, but a heart-health benefit from this form remains unestablished.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality70
The niacin form is clearly identified, which makes the type supplied easy to check. The quality of the inositol contribution cannot be judged with the same confidence.
Ingredient Transparency100
The declared niacin and inositol amounts and forms are stated. Both refer to inositol hexanicotinate, so they should not be read as proof of two separate health effects.
Value For Money100
The declared niacin form has favorable value. The finding concerns the supplement provided per serving, while suitability still depends on the purpose of taking it.
Customer Satisfaction84
Customer feedback is very positive across more than a thousand ratings. That is useful for judging satisfaction but does not establish cardiovascular benefits.
Product Focus0
The supplement is narrowly centered on inositol hexanicotinate. A cardiovascular role for this form is not established, and evidence for a different niacin form cannot simply be applied to it.
- Format
Tablet - Container
- 60 Tablet(s)
- Per serving
- $0.16
- Customer rating
- 4.7 · 1,597 ratings
Goals
No-Flush Niacin 500 mg declares 500 mg inositol hexanicotinate per serving, but the supplied cardiovascular evidence doesn't give this form a role as studied nicotinic-acid support. That leaves no established amount or pathway for this goal; this missing match doesn't prove the ingredient is clinically ineffective.
How this product is rated for Cardiovascular Support
Ingredient fit28
Goal fit
Dose adequacy
Pathways0
Depth
Breadth
Evidence0
Evidence strength
Studied preparation
Formulation logic35
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Niacin (Inositol Hexanicotinate) | 500 mg | |
Inositol (Inositol Hexanicotinate) | 143 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability64
Niacin Form & Goal Alignment
Precursor Source Quality
Dose, Safety & Label Transparency75
Clarity of Chemical Form
Form-Specific Dosage Efficacy
Flush Risk & Safety Labeling
Value100
Price Per Effective Serving
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
- Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
- Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
- Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
- Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
- Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.